ORIC PHARMACEUTICALS, INC. Lessee, Operating Lease, Liability, Undiscounted Excess Amount
ORIC PHARMACEUTICALS, INC. (ORIC) had Lessee, Operating Lease, Liability, Undiscounted Excess Amount of $699.00 thousand as of 2025-12-31, per its 10-K filed 2026-02-23.
Financial Statements › Notes › Leases
us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount · last filed 2026-02-23
- 2025-12-31: Lessee, Operating Lease, Liability, Undiscounted Excess Amount $699.00K.
- 2024-12-31: Lessee, Operating Lease, Liability, Undiscounted Excess Amount $1.22M.
- 2023-12-31: Lessee, Operating Lease, Liability, Undiscounted Excess Amount $1.81M.
- 2022-12-31: Lessee, Operating Lease, Liability, Undiscounted Excess Amount $2.69M.
| Period end | Lessee, Operating Lease, Liability, Undiscounted Excess Amount |
|---|---|
| 2025-12-31 | $699.00K 10-K · filed 2026-02-23 |
| 2024-12-31 | $1.22M 10-K · filed 2025-02-18 |
| 2023-12-31 | $1.81M 10-K · filed 2024-03-11 |
| 2022-12-31 | $2.69M 10-K · filed 2023-03-16 |
| 2021-12-31 | $3.56M 10-K · filed 2022-03-21 |
| 2021-09-30 | $3.77M 10-Q · filed 2021-11-08 |
| 2021-06-30 | $51.00K 10-Q · filed 2021-08-10 |
| 2021-03-31 | $85.00K 10-Q · filed 2021-05-06 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Kardigan, Inc. (KARD) | United States | $1.346B | |
| Tyra Biosciences, Inc. (TYRA) | United States | $1.337B | -12.83 |
| Bicara Therapeutics Inc. (BCAX) | United States | $1.309B | -10.55 |
| First Tracks Biotherapeutics, Inc. (TRAX) | United States | $1.280B | |
| OMEROS CORP (OMER) | United States | $1.456B | 5.50 |
| Ultragenyx Pharmaceutical Inc. (RARE) | United States | $1.456B | -5.62 |
| Avalyn Pharma Inc. (AVLN) | United States | $1.267B | |
| Damora Therapeutics, Inc. (DMRA) | $1.250B | -6.10 | |
| ArriVent BioPharma, Inc. (AVBP) | United States | $1.485B | -10.25 |
| Innoviva, Inc. (INVA) | United States | $1.493B | 4.62 |